In a patient with chronic tension‑type headache who is taking mirtazapine for prophylaxis and now reports a new headache, how should the headache be evaluated and managed?

Evaluation and Management of New Headache in a Patient on Mirtazapine for Chronic Tension-Type Headache

First, rule out medication overuse headache (MOH) and assess for secondary causes, then optimize the existing prophylactic regimen or consider alternative treatments if mirtazapine has failed after an adequate trial.

Initial Assessment Priority

When a patient on mirtazapine for chronic tension-type headache (TTH) presents with a new or worsening headache, your evaluation must systematically address three critical possibilities:

1. Exclude Secondary Headache

• Perform careful history and neurological examination looking for "red flags" 1
• New headache characteristics warrant evaluation for secondary causes before assuming treatment failure 1
• Consider neuroimaging only if there are abnormal neurological findings or concerning features (headache worsened by Valsalva, wakening from sleep, progressive worsening, or new headache in older patients) 2

2. Assess for Medication Overuse Headache (MOH)

This is a critical pitfall that must be actively investigated. Patients with chronic headache frequently develop MOH, which can present as worsening or persistent headache despite prophylactic treatment 1.

• Ask specifically about acute medication use: Simple analgesics used ≥15 days/month or triptans used ≥10 days/month can cause MOH 1
• MOH affects up to 73% of patients with chronic migraine seeking treatment 1
• If MOH is present: Education about medication overuse and withdrawal of the overused medication is essential before any prophylactic treatment can be effective 3

3. Evaluate Mirtazapine Efficacy

Mirtazapine is a second-line prophylactic agent for chronic TTH 4, 5. The key question is whether it has had an adequate trial:

• Adequate trial duration: Prophylactic medications require 2-3 months to manifest clinical benefit 6
• If the patient has been on mirtazapine for <2-3 months, continue the current regimen and reassess
• If adequate trial duration has passed without benefit, consider switching prophylactic agents

Management Algorithm

If MOH is Identified:

1. Patient education about the relationship between frequent acute medication use and headache chronification 3
2. Initiate or optimize prophylaxis (can continue mirtazapine or switch to amitriptyline) 3
3. Structured withdrawal of overused medication:
   • Outpatient withdrawal for most patients
   • Inpatient withdrawal mandatory for opioid overuse 3
   • Use tricyclic antidepressants, antiemetics, or short-course steroids for withdrawal symptoms 3

If Mirtazapine Has Failed After Adequate Trial:

Switch to amitriptyline (30-150 mg/day), which is the first-line prophylactic drug for chronic TTH 6, 4, 7, 5.

• Amitriptyline has superior evidence compared to mirtazapine for chronic TTH prophylaxis 4, 7
• Mirtazapine is explicitly designated as a second-choice drug 4, 5
• The efficacy of prophylactic drugs for TTH is often limited and treatment may be hampered by side effects 4

If the Patient Has Chronic Migraine (Not TTH):

This is an important diagnostic consideration if the headache pattern has changed. Chronic migraine is defined as ≥15 headache days/month for ≥3 months, with ≥8 days/month meeting migraine criteria 1.

For chronic migraine, evidence-based options include:

• Topiramate: The only oral prophylactic with randomized controlled trial evidence in chronic migraine 1
• OnabotulinumtoxinA: The only FDA-approved therapy specifically for chronic migraine prophylaxis 1
• CGRP monoclonal antibodies and atogepant: Effective in chronic migraine with medication overuse 8, 3

Non-Pharmacological Interventions

These should be integrated regardless of the pharmacological approach:

• EMG biofeedback has documented efficacy in TTH 4, 7
• Cognitive-behavioral therapy and relaxation training are likely effective 4, 7
• Physical therapy and aerobic exercise can be used for both TTH and migraine management 8, 4, 7
• Identification and management of trigger factors, stress, sleep disorders, and psychiatric comorbidities 1

Critical Pitfalls to Avoid

1. Do not assume treatment failure without assessing for MOH - this is the most common reason for apparent prophylactic failure
2. Do not use triptans, muscle relaxants, or opioids for TTH 4, 7
3. Avoid frequent analgesic use - limit simple analgesics to <15 days/month and triptans to <10 days/month 1
4. Ensure adequate trial duration (2-3 months) before declaring prophylactic failure 6
5. Monitor for mirtazapine side effects including sedation, weight gain, and potential serotonin syndrome if combined with other serotonergic drugs 9

When to Refer

Consider neurology referral for 1:

• Uncertain diagnosis
• Poor response to first-line prophylactic strategies
• Need for specialized treatments (e.g., onabotulinumtoxinA)
• Persistent headache despite appropriate management